The top executive at Pfizer, a leading producer of COVID-19 vaccines, has tested positive for the virus and says he is experiencing very mild symptoms.
Chairman and CEO Albert Bourla said Monday that he started taking Pfizer's Paxlovid pill treatment and is isolating while he recovers.
Bourla has received four shots of Comirnaty, the COVID-19 vaccine developed by the New York drugmaker along with BioNTech. He said in a brief statement issued by the company that he is confident of a quick recovery.
More than 128 million people in the United States have become fully vaccinated with Pfizer's two-shot vaccine since it entered the market more than a year ago and almost 61 million have received an initial booster shot, according to the Centers for Disease Control and Prevention.
Scientists say the vaccine still offers solid protection against hospitalization and serious illness. But the evolving virus has made it tougher for vaccines to prevent all forms of illness from developing.
Pfizer and another vaccine maker, Moderna, are updating their shots to provide protection against newer versions of the virus for a fall booster campaign.
Paxlovid also has shown in research to be extremely effective at warding off serious illness if it is administered shortly after symptoms start.
Comirnaty and Paxlovid are the top-selling COVID-19 vaccine and treatment on the market. Combined, they brought in nearly USD 17 billion in sales for Pfizer during the recently completed second quarter.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve hit your limit of {{free_limit}} free articles this month, subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Months/month
Smart Essential
₹2,700
1 Year
₹225/Months/month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Unlimited access to all articles
30+ premium stories daily, handpicked by our editor


Complimentary Access to The New York Times
News, Games, Cooking, Audio
Wirecutter & The Athletic
Complimentary Access to Our e-Paper
Digital replica of our daily newspaper
Read, save, share any article


Curated Newsletters on Diverse Topics
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Smart Investment Tips
In-depth stock analysis & insights
The Smart Investor for wealth growth tips


Access to Extensive Historical Archives
Repository of articles and publications dating back to 1997
Ad-free Reading Experience
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Repository of articles and publications dating back to 1997